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Abstract
Introduction: An over-expression of CD19 has been shown in B cells of systemic sclerosis (SSc) and B cells are
thought to contribute to the induction of skin fibrosis in the tight skin mouse model. The aim was to define the
outcome on safety and the change in skin score after rituximab therapy in SSc patients and to correlate the clinical
characteristics with the levels of interleukin (IL)-6 and with the immune cell infiltrate detected by
immunohistochemistry.
Methods: Nine patients with SSc with mean age 40.9 ± 11.1 years were treated with anti-CD20, 1 g at time 0 and
after 14 days. Skin biopsy was performed at baseline and during the follow-up. B-cell activating factor (BAFF) and
IL-6 levels were also determined at the follow-up times.
Results: After 6 months patients presented a median decrease of the skin score of 43.3% (range 21.1-64.0%), and a
decrease in disease activity index and disease severity index. IL-6 levels decreased permanently during the follow
up. After treatment, a complete depletion of peripheral blood B cells was observed in all but 2 patients. Only 3
patients presented CD20 positive cells in the biopsy of the involved skin at baseline.
Conclusions: Anti-CD20 treatment has been well tolerated and SSc patients experienced an improvement of the
skin score and of clinical symptoms. The clear fall in IL-6 levels could contribute to the skin fibrosis improvement,
while the presence of B cells in the skin seems to be irrelevant with respect to the outcome after B cell depletion.
Trial registration: ISRCTN77554566.
Introduction
Although the pathogenesis of systemic sclerosis (SSc)
remains unknown, the B cell abnormalities characterized
by autoantibody production [1], hyper-g-globulinemia
and polyclonal B cell hyperactivity [2] are thought to
play an important role in the disease. It has been pre-
viously described that SSc patients have distinct
abnormalities of blood homeostasis and B cell compart-
ments, characterized by expanded naïve cells and acti-
vated, but diminished, memory B cells [3]. Furthermore,
the expression of CD19, a critical signal transduction
molecule of B cells that regulates autoantibody produc-
tion, is significantly increased in memory and naïve B
cells in SSc patients [3,4]. Analysis of DNA microarrays
of cutaneous biopsies from diffuse SSc (dSSc) patients
demonstrated a higher expression of clusters of genes of
CD20-positive cells [5].
In the tight-skin mice, a genetic model of human SSc,
the CD19 signaling pathway appeared to be constitu-
tively activated [6,7] and the loss of CD19 expression
significantly up-regulated surface IgM expression, com-
pletely abrogated hyper-g-globulinemia and autoantibody
production, and also inhibited IL-6 production [7].
Additionally, in this animal model, the down-regulation
of B cell function led to a decrease in skin fibrosis
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induced SSc mouse model, another animal model that
shares many characteristics with human SSc, CD19 defi-
ciency inhibited the development of skin and lung fibro-
sis, hyper-g-globulinemia, and autoantibody production
[9]. Thus, B cells could have a relevant impact on the
development of fibrotic changes as reported in the
mouse scleroderma models [6-9] and also in CCl4-
induced liver injury, in an antibody- and T cell-indepen-
dent manner [10].
In several studies focusing on the pathogenesis of SSc,
the increased levels of IL-6 in the skin, serum, and
bronchoalveolar lavage fluid of SSc patients suggest a
role of this cytokine in promoting fibrosis by enhancing
inflammation [11-13]. Furthermore, immunohistochem-
i s t r yd a t ad e m o n s t r a t e da no ver-expression of IL-6 on
endothelium and fibroblasts of involved skin of sclero-
derma patients compared with normal skin [14]. SSc
dermal fibroblasts constitutively produce about a four-
fold increase in IL-6 levels with respect to healthy con-
trols fibroblasts [15] and secretion of IL-6 from lung
fibroblast is induced by SSc lung-derived B cells [16].
Recently, it has been reported that B-cell activating fac-
tor (BAFF), an essential component of B cell homeosta-
sis and a potent B-cell survival factor associated with
autoimmune disease in humans, is increased in SSc
patients compared with healthy controls [17]. In the
tight-skin mice, BAFF antagonist augmented anti-fibro-
genic cytokines and inhibited the development of skin
fibrosis. Finally, after BAFF stimulation, B-cells had a
significantly enhanced ability to produce IL-6 [18].
Two recent open-label studies reported the safety of
anti-CD20 treatment in SSc patients; despite both studies
describing a decrease in myofibroblast score on serial
skin biopsies after treatment, only one reported an
improvement in skin score [19,20]. In these two studies,
lung function remained stable during follow up, whereas
a case report suggested a possible beneficial role of rituxi-
mab on lung involvement in scleroderma disease [21].
The primary aim of the current prospective study was
to evaluate the changes in the skin score from baseline
to at least 6 up to 36 months of follow up after anti-
CD20 therapy. Secondary aims were to assess the poten-
tial efficacy of rituximab on lung function, to investigate
the modification in IL-6 and BAFF serum levels as bio-
logical parameters of disease activity, and to correlate
the clinical characteristics with the immune cell infil-
trate detected by immunohistochemistry.
Materials and methods
Patients and treatment
Nine patients with progressive cutaneous SSc involve-
ment, who showed a worsening of skin score higher than
10% after the conventional cyclophosphamide therapy
[22] (up to 6 g), were treated with rituximab, two infu-
sions of 1000 mg, two weeks apart, together with 100 mg
methylprednisolone at each infusion, after three months
of wash-out. All patients fulfilled the American College
of Rheumatology classification criteria for scleroderma
[23] and gave their informed consent to enter the study,
which was approved by our Ethics Institutional Commit-
tee. All patients accepted that their biographical and clin-
ical information could be eventually published.
Inclusion criteria were: age older than 18 years, a wor-
sening in skin score higher than 10% after the conven-
tional cyclophosphamide therapy, and a diffuse disease
with trunk involvement. Exclusion criteria were: rest
dyspnoea or signs and symptoms of heart failure, serious
and uncontrolled coexisting diseases, infection, immuno-
deficiency or a history of tuberculosis contact, or cancer.
None of the patients was taking corticosteroids daily.
Three patients were re-treated with rituximab 1 g × 2
(days 1 to 15): the first patient because after 18 months
she presented with a reactivation of her arthritis, while
the other two patients were re-treated after 12 months
because they presented a precocious and quicker B cell-
recovery at months 3 and 7 (CD19 >4.5%).
There were eight women and one man, with a mean
(standard deviation (SD))age of 40.9 ± 11.1 years, and a
median disease duration of 2.0 (range:1.0 to 12.0) years.
Seven patients had an early disease, defined as a disease
duration less than three years since the occurrence of
Raynaud’s phenomenon. All patients presented a diffuse
skin disease (dSSc); moreover, six (66.7%) had antiScl70-
Abs positivity and three (33.3%) only presented antinuc-
lear antibodies (ANA) positivity (Table 1) [24]. All nine
patients continued to receive iloprost (by an infusion of
0.5 to 2 ng/kg/minute for five days every two months),
calcium-channel blockers (nifedipine 20 to 40 mg/day)
and acetylsalicylic acid from the moment of medical
diagnosis. One of the two patients with long disease also
presented with a metacarpophalangeal and wrist arthritis
Table 1 Demographic and clinical characteristics of nine
patients treated with rituximab
Age (years) (mean (SD)) 40.9 (11.1)
(median (range)) 41.5 (21.0-55.0)
Disease duration (months) (mean (SD)) 49.0 (73.1)
(median (range)) 24.0 (12-240)
Female (number,%) 8 (88.9)
Male (number,%) 1 (11.1)
ANA positivity (number,%) 9 (100)
Anti-Scl70 positivity (number,%) 6 (66.7)
Follow-up (months)(mean (SD)) 16.7 (12.6)
(median (range)) 12 (6-36)
The values are indicated as the mean (SD), median (range) or percentage.
ANA, antinuclear antibodies; SD, standard deviation.
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levels. Both these patients received methotrexate 15 mg/
week after cyclophosphamide, one for treatment of
arthritis and the other for myositis therapy. Both
patients experienced a worsening of their skin fibrosis
despite this therapy.
The extent of skin involvement was evaluated by the
Rodnan skin score, performed by two observers and
their results averaged [25]. Every three months, activity
index [26] and severity index were assessed [27] and
Global Health Status (GH) and Health Assessment
Questionnaire (HAQ) were administered to patients to
evaluate the influence of the disease on daily functions.
At the same time intervals, blood samples were collected
to determine IL-6 and BAFF levels and to count CD19-
positive cells by flow cytometry.
Internal organ involvement
All nine patients underwent pulmonary function tests to
define forced vital capacity (FVC) and diffusing capacity
for carbon monoxide (DLCO) before treatment and
every six months. High-resolution computed tomogra-
phy (HRCT) was performed before treatment and every
12 months. Renal involvement was defined as a sclero-
derma crisis or the presence of proteinuria or elevation
in creatinine serum level. Creatinine levels and urine
analysis were performed every three months. Cardiac
involvement was defined as the presence of conduction
disturbance, left ventricular ejection fraction (LVEF) less
than 50%, pulmonary artery systolic pressure (PASP)
more than 35 mmHg or presence of myocarditis; elec-
trocardiography (ECG) and echocardiography were per-
formed at the beginning of the treatment and every six
months. Gastrointestinal involvement was defined as the
presence of gastro-esophageal reflux symptoms or the
evidence of gastrointestinal motility disturbance by bar-
ium swallow performed before treatment.
Biological marker detection
Serum levels of IL-6 and BAFF (R&D Systems, Minnea-
polis, MN, USA) were measured using an ELISA, as
described by the manufacturer. Erythrocyte sedimenta-
tion rate, total immunoglobulin (Ig) G, IgM and IgA
were part of the routine clinical care of each patient.
ANA were determined by indirect immunofluorescence
using Hep-2 cells as substrates and autoantibodies speci-
ficities were further assessed by ELISA (Shield, Dundee,
UK). Peripheral blood CD19-positive cell count was
obtained by flow cytometry every three months.
Skin biopsies and immunohistochemical analysis
Skin biopsies were performed in seven patients, who
gave their informed consent, before treatment and in
the five patients that achieved 12 months of follow up
from the beginning of anti-CD20 therapy. Four healthy
controls gave their informed consent to undergo fore-
arm skin biopsy. In dSSc patients, cutaneous specimens
were taken from the distal forearm for the clinically
involved skin and from the buttock for clinically unin-
volved skin. The biopsies were fixed into 10% formalin
for two hours followed by paraffin inclusion for histolo-
gical and immunohistochemical analysis.
Immunohistochemistry was carried out on 5 μm thick
sections on polylysine-coated slides. After routine depar-
affinization and rehydration, antigen retrieval was per-
formed. Slide-mounted sections were heated in a
microwave oven at 700 watt twice for four minutes in
10 mmol/L sodium citrate buffer (pH 6.0). Tissue sec-
tions were allowed to cool at room temperature (RT).
Quenching of endogenous peroxidase activity was per-
formed with Tris-buffered saline (TBS; pH 7.6) contain-
ing 2% hydrogen peroxide for 10 minutes at RT.
Blocking was performed with 20% normal goat serum in
TBS for 60 minutes at RT.
The sections were incubated with anti-CD3 and anti-
CD20 mouse monoclonal antibodies (mAbs, Clone PS1
and L26 respectively; IgG2a;Y l e m ,R o m e ,I t a l y )b o t h
1:100 diluted in blocking solution (20% normal goat
serum in TBS) for 60 minutes at RT. Then, the Super
Picture Polymer detection kit (Zymed Laboratories,
South San Francisco, CA, USA) was used for 30 minutes
at RT. The chromogenic reaction was developed with
3,3’-diaminobenzidine tetrahydrochloride solution
(Zymed Laboratories, South San Francisco, CA, USA).
The nuclei were lightly counterstained with Mayer’s
hematoxylin. Negative controls without primary antibo-
dies were performed for all reactions. As all mAbs were
of IgG2a isotype, mouse mAb IgG2a served as an iso-
type-specific control. Human tonsil specimens were
used as positive controls for both antibodies. All con-
trols were run under the same conditions and the same
IgG concentrations were used for the respective primary
antibodies. Positive cells were counted by two indepen-
dent observers in six randomly selected fields (total
area: 7.38 mm
2) for each section at × 400 magnification.
Differences between observers about staining evaluation
were resolved by consensus. The total number of posi-
tive cells was calculated.
Statistical analysis
All analyses were carried out using SPSS 15.0 (Chicago,
IL, USA). Categorical variables were expressed as
numbers, and quantitative variables as mean ± SD if
normally distributed, and asm e d i a np l u sr a n g ei fn o t .
Non-normally distributed data were compared using the
Mann-Whitney’s test, and the Wilcoxon’s test for paired
data. A value of P < 0.05 was considered statistically
significant.
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Skin score, activity and severity indices
All nine SSc patients treated with rituximab experienced
an improvement of the skin score, activity index, sever-
ity index, HAQ and GH during the follow up if com-
pared to pre-treatment values (Table 2 and Figure 1).
Neither infections nor infusion reactions were observed.
T h eo n l ys e r i o u sa d v e r s ee v e n tw a st h ed e v e l o p m e n to f
an occult breast cancer, which was thought to be unre-
lated to the study medication. The mean follow up was
16.7 ± 12.6 months: all patients reached a six-month fol-
low up, five patients reached a 12-month follow up, four
patients reached an 18-month follow up, three patients
reached a 24-month follow up and two patients reached
a 36-month follow up.
Interestingly, in all nine patients treated with rituxi-
mab, the skin score improved gradually over time (Fig-
ure 1 and Table 2). After six months, the skin score
improved in all the patients, decreasing from 21.1 ± 9.0
to 12.0 ± 6.1 (P = 0.001), with a median of improvement
of 43.3% (range: 21.1 to 64.0%). Considering the last
observation carried forward in each patient, the median
skin improvement was 57.1% (range: 21.2 to 76.2).
After six months, the activity index decreased from
4.8 ± 1.3 to 1.2 ± 1.2 (P = 0.01) and the severity index
from 10.5 ± 3.2 to 7.2 ± 2.8 (P =0 . 0 1 ;F i g u r e1a n d
Table 2). All patients reported an improvement of their
conditions as supported by the decrease in HAQ from
0.9 ± 0.7 to 0.4 ± 0.5 (P = 0.01) and an increase in GH
from 59.4 ± 20.9 to 82.8 ± 16.6 (P = 0.01; Table 2). The
only patient who did not present an improvement of the
activity and severity indices, HAQ and GH, had a long
disease duration.
Organ involvement
The FVC and DLCO values showed no significant dif-
ferences at follow up (96.8 ± 18.9% and 58.4 ± 14.2% of
predicted value, respectively) compared with baseline
(91.6 ± 20.7% and 58.0 ± 15.8% of the predicted value,
respectively; P = ns for both comparison). Four (44.4%)
patients presented an improvement higher than 10% of
FVC, (median increase 14.9% (range: 11.8% to 29.5%)).
None of the patients presented a reduction in FVC con-
sidered clinically significant (>10%), but one patient
showed a decrease in FVC values suggesting a trend to
a progression of her restrictive lung disease [28,29].
Two patients (22.2%) presented an isolated reduction
of DLCO higher than 15%, both with an improvement
in FVC values higher than 10% and with a stable echo-
cardiography evaluation and no sign of pulmonary arter-
ial hypertension. On the other hand, a clinical significant
improvement in DLCO was reported in two patients
(22.2%) [28,29] (Table 3).
None of the patients showed signs of new or progres-
sive cardiac disease, with stable ejection fractions and
no modification on ECGs; none of the patients experi-
enced renal crisis or symptoms suggesting progressive
gastrointestinal disease.
Biological markers
At baseline, patients presented high levels of IL-6 (3.7 ±
5.3 pg/ml), that permanently decreased after six months
(0.6 ± 0.9 pg/ml, P = 0.02; Table 2 and Figure 2a).
Three months after the rituximab infusion, circulating B
cells evaluated by flow-cytometry were depleted (periph-
eral blood CD19 <0.1%) in all but one patient, and
between 6 and 12 months they begun to repopulate.
Upon B-cell depletion, BAFF levels increased relative to
baseline (baseline: 1233.5 ± 683.3 pg/ml vs six months:
3257.8 ± 1571.8 pg/ml), while in one patient the BAFF
levels did not increase until the time of repopulation
(Figure 2b).
The autoantibody titers and IgG and IgA levels did
not vary over the study period, while IgM levels
decreased from 133.7 ± 21.7 mg/dl to 90.9 ± 28.9 mg/dl
at six months follow up (P = 0.008), and to 83.0 ± 18.7
after 12 months of follow up (P = 0.04; Table 2).
Before rituximab treatment, one patient presented
myositis with high creatine kinase levels, which
decreased significantly after anti-CD20 treatment (data
not shown). Creatine kinase levels remained within the
normal range during the 36 months of follow up. The
only patient with a long disease duration who did pre-
sent the less significant clinical improvement, showed
an important amelioration of her arthritis, with a change
of disease activity score (DAS) from 4.3 to 2.0.
Three (42.9%) out of the seven patients, who under-
went skin biopsies before treatment, presented CD20-
positive cells on biopsies of the clinically involved skin
and uninvolved skin; only one patient of these three
repeated the biopsy after 12 months and it showed a
depletion of dermal B cells. The other two patients were
treated only for six months and they did not agree to a
repeat biopsy.
CD3 lymphocytes were found, predominantly, in a
perivascular location in the mid and deeper portion of
the dermis in all the involved and uninvolved skin biop-
sies of patients before and after treatment with anti-
CD20. Figure 3 illustrates the presence of B cells (a) and
T cells (b) in forearm biopsy in patient number three
before therapy. The mean number of CD3-positive cells
in skin biopsies of four healthy subjects was 8.0 ± 2.0
and none presented B cells (data not shown). Before
treatment, the mean number of CD3-positive cells was
54.7 ± 27.9 in involved skin and 65.6 ± 39.7 in unin-
volved skin (P = ns; Figure 3). After treatment, a similar
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Page 4 of 10Table 2 Efficacy of rituximab on clinical and biologic parameters of nine SSc patients treated with anti-CD20 during
the follow up
Baseline After 3
Months
After 6
Months
After 12
months*
After 18
months**
After 24
months***
After 36
months****
Rodnan skin score
(mean (SD)) 21.1 (9.0) 15.2 (6.0) 12.0 (6.1) 7.0 (4.0) 7.0 (3.5) 5.0 (2.0) 4.0 (1.4)
(median (range)) 19.0 (7-36) 15.0 (5-27) 10.0 (4-26) 8.0 (3-14) 7.5 (3-10) 5.0 (3-7) 4.0 (3-5)
Disease activity index
(mean (SD)) 4.8 (1.3) 2.0 (1.2) 1.2 (1.2) 0.9 (1.0) 1.0 (1.3) 1.3 (1.4) 1.7 (1.8)
(median (range)) 4.5 (3.5-7.0) 2.0 (0.5-3.5) 0.5 (0.5-3.5) 0.5 (0.5-3.0) 0.5 (0.5-3.0) 0.5 (0.5-3.0) 1.7 (0.5-3.0)
Disease severity index
(mean (SD)) 10.5 (3.2) 8.3 (2.9) 7.2 (2.8) 6.2 (2.8) 6.7 (2.2) 7.7 (1.5) 8.5 (0.7)
(median (range)) 11.0 (6-15) 7.0 (4-13) 6.0 (4-11) 6.0 (3-9) 7.0 (4-9) 8.0 (6-9) 8.5 (8-9)
HAQ
(mean (SD)) 0.9 (0.7) 0.5 (0.5) 0.4 (0.5) 0.3 (0.7) 0.3 (0.6) 0.3 (0.6) 0.6 (0.6)
(median (range)) 0.8 (0.1-2.4) 0.4 (0-1.6) 0.2 (0-1.5) 0 (0-1.5) 0 (0-1.2) 0 (0-1.1) 0 (0-1.3)
GH (mean (SD)) 59.4 (20.9) 74.4 (16.5) 82.8 (16.6) 86.0 (10.8) 82.5 (21.8) 82.5 (17.7) 82.5 (17.7)
(median (range)) 60.0 (30-85) 80.0 (50-95) 90.0 (50-95) 90.0 (70-95) 92.5 (50-95) 82.5 (70-95) 82.5 (70-95)
Blood CD20%
(mean (SD)) 6.8 (3.9) 0.7 (1.5) 1.7 (2.4) 3.0 (2.7) 2.0 (1.6) 1.0 (1.5) 3.0 (3.3)
(median (range)) 6.0 (2.5-14.7) 0.1 (0.1-4.6) 1.0 (0.1-7.0) 4.0 (0.3-7.0) 2.0 (0.2-3.0) 1.0 (0.2-3.0) 3.0 (0.3-5.0)
IgG mg/ml
(mean (SD)) 1055 (233) 1001 (191) 1021 (158) 1028 (46.6) 946.2 (178) 944 (315) 951 (69)
(median (range)) 1140 (729-1340) 932 (884-1440) 1030 (802-1220) 1005 (1000-1110) 938 (738-1170) 896 (656-1280) 951 (902-1000)
IgA mg/ml
(mean (SD)) 184.0 (44.4) 174.5 (39.2) 177.8 (63.5) 179.4 (69.8) 152.5 (59.9) 139.0 (67.5) 100.0 (24.0)
(median (range)) 183.5 (119-249) 183.5 (119-262) 200.0 (75-262) 168.5 (93-281) 154.0 (79-222) 136.0 (73-208) 100.0 (83-117)
IgM mg/ml
(mean (SD)) 133.7 (21.7) 86.0 (12.8) 90.9 (28.9) 83.0 (18.7) 61.5 (6.7) 43.3 (10.6) 71.0 (1.4)
(median (range)) 132.5 (95-157) 91.0 (56-136) 96.0 (40-136) 73.0 (64-105) 61.5 (54-69) 45.0 (32-53) 71.0 (70-72)
BAFF pg/ml
(mean (SD)) 1233.5 (683.3) 1719.4 (1264.3) 3257.8 (1571.8) 2057.0 (912.5) 2988.0 (1804) 3520.0 (1999) 3608.0 (2824)
(median (range)) 875.6
(683-2601)
1008.6
(356-4038)
3141.8
(723-6682)
1580.6
(1321.6-3280)
2406.2
(1534-5605)
3224.8
(1684-5651)
3608.0
(1610-5605)
IL6 pg/ml
(mean (SD)) 3.7 (5.3) 1.0 (1.2) 0.6 (0.9) 0.4 (0.4) 1.2 (2.0) 0.1 (0.1) 0.1 (0.1)
(median (range)) 1.7 (0.1-16.9) 0.1 (0.1-3.6) 0.1 (0.1-2.8) 0.4 (0.1-0.8) 0.25 (0.1-4.2 0.1 (0.1-0.1) 0.1 (0.1-0.1)
Clinical and biological parameters of nine SSc patients treated with anti-CD20 at baseline, after 3, 6, 12, 18, 24 and 36 months. The values are indicated as the
mean (SD) and median (range). All patients had trunk skin involvement.
*Five SSc patients reached 12 months of follow up. **Four SSc patients reached 18 months of follow up. ***Three SSc patients reached 24 months of follow up.
*****Two patients reached 36 months of follow up.
BAFF, B-cell activating factor; GH, Global Health Status; HAQ, Health Assessment Questionnarie; Ig, immunoglobulin; SD, standard deviation; SSc, systemic
sclerosis.
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(44.3 ± 24.0) and in uninvolved skin (62.7 ± 23.4) of
the five patients who underwent skin biopsies after
12 months.
Discussion
The results of our study suggest that B cell depletion in
patients with early and progressive dSSc, leads to a clini-
cally relevant decrease in skin involvement and to a sta-
bilization of organ function. The only patient who
showed a less clear-cut response either in terms of
severity and activity indexes was the one with a long-
standing disease.
In our study, the safety of anti-CD20 treatment in SSc
patients was also confirmed in up to 36 months of fol-
low up. The observed skin score improvement is more
than expected as the spontaneous improvement in
patients with similar disease, and comparable with the
study by Smith and colleagues [19]. Recently, two stu-
dies assessed the safety of anti-CD20 treatment in scler-
oderma patients. In the first open-label trial, eight SSc
patients experienced a skin score improvement up to
43% after 24 weeks from the beginning of anti-CD20
treatment [19], while in the second, a cohort of 15 SSc
patients, with a follow up of 12 months, showed no
improvement in the skin score [20]. Only the first group
used the corticosteroids premedication.
In these two studies, all SSc patients, as in our study,
had an early diffuse disease and patients were similar for
age, disease duration and clinical characteristics [19,20].
It is interesting to note that despite little changes
reported in the skin score after rituximab treatment in
the largest cohort, a decrease in myofibroblast score was
observed in several patients [20]. As the myofibroblast
score correlates with the skin thickness score [20,30],
these data suggest that a decrease in myofibroblast score
Figure 1 Clinical improvement during follow up in nine systemic sclerosis patients treated with anti-CD20. Clinical improvement in the
nine patients treated with anti-CD20 during the follow-up times (3, 6, 12, 18, 24 and 36 months). Skin score, blood CD20 levels, severity index
and activity index were assessed at baseline (0) and after 3, 6, 12, 18, 24 and 36 months. In the first graph precyclophosphamide (preCYP) skin
score and skin score at time 0 (time of beginning of rituximab (RTX)) are reported. Each line represents the modification of different parameters
in each patient during the follow up. Each symbol (on the left) represents one patient and corresponds to the number of the patient of Table 3.
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oderma skin fibrosis. Furthermore, Lafyatis and collea-
gues reported the presence of B cells in all but one skin
specimen at baseline and a complete or nearly complete
depletion of dermal B cells six months after administra-
tion of rituximab [20]. This suggests a biological effect
on the skin after drug administration that could with
new courses of the drug lead to a clinical skin improve-
ment. In fact, we treated patients with a progressive
cutaneous disease after conventional cyclophosphamide
therapy. Moreover, we decided to re-treat two of our
patients, because they presented a slower improvement
of the skin score in the first six months of follow up
and an earlier repopulation of B cells, similar to the
data reported by the Lafyatis and colleagues, in which
the majority of patients presented a precocious recovery
of B cells between 6 and 12 months [20].
Interestingly, none of the SSc patients in the current
study treated with anti-CD20 showed a progression of
major end-organ involvement in a population with early
diffuse disease that had a relatively high risk of organ
complication. Parameters of internal organ involvement
remained stable, but a further follow up in a more con-
sistent group of patients is needed before drawing any
conclusions.
The clear fall in IL-6 levels observed in our study is in
agreement with findings obtained in a mouse model
after B cell depletion [8]. This fall could be related, at
least for the first stages, to the high dose of methylpred-
nisolone used for the premedication in ours and the
cohort of patients in the study by Smith and colleagues
[19], but considering the follow times of evaluation (3 to
6 to 12 months) it has to be related to the rituximab
treatment. This may suggest that IL-6 might contribute
to the active phase of the disease. The decrease in IL-6
at the systemic levels could be the biological premise of
the improvement in skin fibrosis. In fact, it has been
previously reported that chronic IL-6 administration
induces an increased synthesis of collagen in dermal
fibroblasts [31] and in the liver [32]. Furthermore, IL-6
has been demonstrated to enhance resistance of lung
fibroblasts to apoptosis, contributing to the fibrotic
effect [33].
Immunohistochemistry clearly demonstrated the pre-
sence of T cells either in uninvolved or in involved skin,
but B cells were seen only in some patients, as pre-
viously reported [5,19]. These data suggest that the
most relevant contribution of B cells comes from the
systemic pool. In fact, it appears clear that the response
of skin fibrosis to B cell depletion does not rely on the
presence of B cells in the skin, because most of our
treated patients had no B cells, but very likely depends
upon the general contribution to the autoimmune
derangement given by the B cell compartments in
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Page 7 of 10Figure 2 (a) IL-6 and (b) BAFF levels at baseline and during follow up. IL-6 and B-cell activating factor (BAFF) levels evaluated in nine
patients treated with anti-CD20 at baseline and during the follow up. (a and b) Each line represents the modification of IL-6 and BAFF
parameters in each patient during the follow up. Each symbol (on the right) represents one patient and corresponds to the number of the
patient of Table 3.
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Page 8 of 10lymphoid organs. B cells, with their multiple mechan-
isms as antibody-producing cells, antigen-presenting
cells and profibrotic and proinflammatory cytokines pro-
ducing cells (IL-6, IL-4, transforming growth factor-b),
seem to be of great impact in the development of fibro-
sis. Thus, their modulation could inhibit skin fibrosis, as
reported in the scleroderma mouse model [8], but the
data on BAFF levels need to be interpreted since, as
observed in patients with Sjogren’ss y n d r o m e[ 3 4 ]o r
rheumatoid arthritis [35], the levels went up after B cell
depletion.
Conclusions
Our data suggest that anti-CD20 treatment is well tol-
erated and that dSSc patients experience an improve-
ment of the skin score and of clinical symptoms. The
clear fall in IL-6 levels may contribute to the skin
fibrosis improvement, while the presence of B cells in
the skin seems to be irrelevant with respect to the out-
come after B cell depletion. Although we cannot draw
any conclusion due to the limited number of cases, the
response in the early disease patients was striking sug-
gesting that a trial is warranted to confirm these preli-
minary data.
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